Zomedica Corp. announced the commercial launch of its second equine focused assay - Cortisol for equine serum - for the point-of-care TRUFORMA®? diagnostic platform.

The first days of a foal's life can be the most challenging, as illness during this time can cause a foal's health and survival chances to change rapidly. The TRUFORMA platform addresses a $1.5 billion annual recurring revenue opportunity in the US, and with CE marking secured in June, is now positioned to expand into the European veterinary diagnostics market, which is forecast to surpass $3.6 billion by 2028. The TRUFORMA Cortisol assay for equine serum will be available for veterinarians to order directly from Zomedica in July.